Search Results
Your search for ,foR matches 32393 pages
Showing 17151 - 17200
Levi Garraway, MD, PhD, on Drug Development and the Cost of Researching and Treating Cancer
Levi Garraway, MD, PhD, Senior Vice President, Global Development & Medical Affairs, Eli Lilly, speaks during Panel 4: Drug Development and the Cost of Researching and Treating Cancer at The Policy, Politics and Law of Cancer, presented by The Solomon Center for Health Law and Policy at Yale...
Deborah Schrag, MD, MPH, on Cancer, Health Justice, and Disparities
Deborah Schrag, MD, MPH, Chief, Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute; Professor of Medicine, Harvard Medical School, speaks during Panel 3: Cancer, Health Justice, and Disparities at The Policy, Politics and Law of Cancer, presented by The...
Blase Polite, MD, on Cancer, Health Justice, and Disparities
Blase Polite, MD, Associate Professor of Medicine, University of Chicago Medical Center, speaks during Panel 3: Cancer, Health Justice, and Disparities at The Policy, Politics and Law of Cancer, presented by The Solomon Center for Health Law and Policy at Yale Law School, in collaboration with...
Otis Brawley, MD, on Cancer, Health Justice, and Disparities
Otis Brawley, MD, Chief Medical Officer, American Cancer Society, speaks during Panel 3: Cancer, Health Justice, and Disparities at The Policy, Politics and Law of Cancer, presented by The Solomon Center for Health Law and Policy at Yale Law School, in collaboration with Smilow Cancer Hospital and...
Lee Newcomer, MD, MHA, on The Business of Cancer
Lee Newcomer, MD, MHA, Senior Vice President, Oncology, Genetics and Women’s Health, UnitedHealthcare, speaks during Panel 2: The Business of Cancer at The Policy, Politics and Law of Cancer, presented by The Solomon Center for Health Law and Policy at Yale Law School, in collaboration with Smilow...
Randall Oyer, MD, on The Business of Cancer
Randall Oyer, MD, Medical Director, Oncology Program, Lancaster General Hospital, speaks during Panel 2: The Business of Cancer at The Policy, Politics and Law of Cancer, presented by The Solomon Center for Health Law and Policy at Yale Law School, in collaboration with Smilow Cancer Hospital and...
Ed Benz, MD, on The Business of Cancer
Ed Benz, MD, President and CEO Emeritus, Dana-Farber Cancer Institute, speaks during Panel 2: The Business of Cancer at The Policy, Politics and Law of Cancer, presented by The Solomon Center for Health Law and Policy at Yale Law School, in collaboration with Smilow Cancer Hospital and Yale Cancer...
Abe Lopman, MBA, on The Business of Cancer
Abe Lopman, MBA, Senior Vice President, Operations; Executive Director, Smilow Cancer Hospital at Yale New Haven, speaks during Panel 2: The Business of Cancer at The Policy, Politics and Law of Cancer, presented by The Solomon Center for Health Law and Policy at Yale Law School, in collaboration...
Richard Schilsky, MD: Is the Federal Government a Productive Partner in Cancer Policy?
Richard Schilsky, MD, Chief Medical Officer, ASCO, speaks during Panel 1: Is the Federal Government a Productive Partner in Cancer Policy? at The Policy, Politics and Law of Cancer, presented by The Solomon Center for Health Law and Policy at Yale Law School, in collaboration with Smilow Cancer...
Following Nutrition and Exercise Guidelines May Prolong Survival in Stage III Colon Cancer
A diet high in whole grains, fruits, and vegetables—along with exercise and maintaining a healthy body weight—can improve the 5-year survival rate for patients with stage III colorectal cancer, according to a new report published by Van Blarigan et al in JAMA Oncology. The findings...
Pembrolizumab Monotherapy in NSCLC Meets Primary Endpoint in Phase III KEYNOTE-042 Study
On April 9, the phase III KEYNOTE-042 trial evaluating pembrolizumab (Keytruda) as monotherapy for the first-line treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC, including nonsquamous or squamous histologies) met its primary endpoint of overall survival (OS). An ...
Use of Indwelling Pleural Catheter for Outpatient Talc Administration in Treatment of Malignant Pleural Effusion
In a UK study reported in The New England Journal of Medicine, Bhatnagar et al found that outpatient talc vs placebo administration via indwelling pleural catheter was associated with a higher rate of pleurodesis in patients with malignant pleural effusion. Study Details In the study, a target of ...
Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC
In a phase II study reported in the Journal of Clinical Oncology, Wu et al found that crizotinib (Xalkori) was highly active in East Asian patients with ROS1-positive advanced non–small cell lung cancer (NSCLC). Study Details In the study, 127 patients from 37 sites in China, Japan,...
Nancy Goodman, JD, MPP: Is the Federal Government a Productive Partner in Cancer Policy?
Nancy Goodman, JD, MPP, Executive Director, Kids V Cancer, speaks during Panel 1: Is the Federal Government a Productive Partner in Cancer Policy? at The Policy, Politics and Law of Cancer, presented by The Solomon Center for Health Law and Policy at Yale Law School, in collaboration with Smilow...
Nancy Goodman, JD, MPP: Is the Federal Government a Productive Partner in Cancer Policy?
Nancy Goodman, JD, MPP, Executive Director, Kids V Cancer, speaks during Panel 1: Is the Federal Government a Productive Partner in Cancer Policy? at The Policy, Politics and Law of Cancer, presented by The Solomon Center for Health Law and Policy at Yale Law School, in collaboration with Smilow...
Nancy Goodman, JD, MPP: Is the Federal Government a Productive Partner in Cancer Policy?
Nancy Goodman, JD, MPP, Executive Director, Kids V Cancer, speaks during Panel 1: Is the Federal Government a Productive Partner in Cancer Policy? at The Policy, Politics and Law of Cancer, presented by The Solomon Center for Health Law and Policy at Yale Law School, in collaboration with Smilow...
Nut Consumption in Patients With Stage III Colon Cancer
People with stage III colon cancer who regularly eat tree nuts are at significantly lower risk of cancer recurrence and mortality than those who don’t, according to findings published by Fadelu et al in the Journal of Clinical Oncology.1 Study Findings The study followed 826 participants in the...
Wendy S. Harpham, MD, FACP, Writes Gift Book to Change the Conversation About Hope for Cancer Survivors
Recently, Curant House announced the publication of Healing Hope: Through and Beyond Cancer by Wendy S. Harpham, MD, FACP, a physician-survivor of non-Hodgkin lymphoma and award-winning thought leader in survivorship. In this book (her eighth), Dr. Harpham presents 50 illness-related aphorisms in...
AACR 2018: Pilot Study of Neoadjuvant Nivolumab in Resectable NSCLC
In a pilot study reported at the 2018 American Association for Cancer Research (AACR) Annual Meeting (Abstract CT079) and in The New England Journal of Medicine by Forde et al, neoadjuvant nivolumab therapy was found to be feasible and active in patients with resectable non–small cell lung...
Axicabtagene Ciloleucel CAR T-Cell Therapy Active in Refractory Large B-Cell Lymphoma
As reported at the 2017 American Society of Hematology (ASH) Meeting & Exposition and in The New England Journal of Medicine by Sattva S. Neelapu, MD, of The University of Texas MD Anderson Cancer Center, and colleagues, a phase II trial has shown high activity of autologous anti-CD19 chimeric...
AACR 2018: Boosting T-Cell Memory May Result in Longer-Lasting Responses in Patients Treated With Checkpoint Blockade Immunotherapies
Some T cells have excellent memories. These subtypes—known as memory T cells—may explain why some immunotherapies are more effective than others and could potentially lead to researchers designing more effective studies using combination checkpoint blockade treatments, according to...
AACR 2018: New Liquid Biopsy–Based Cancer Model Reveals Data on Chemoresistance in SCLC
Small cell lung cancer (SCLC) accounts for 14% of all lung cancers and is often rapidly resistant to chemotherapy, resulting in poor clinical outcomes. Treatment has changed little for decades, but a study at The University of Texas MD Anderson Cancer Center offers a potential explanation for...
AACR 2018: Adjuvant Pembrolizumab in High-Risk Stage III Melanoma
As reported at the 2018 American Association for Cancer Research (AACR) Annual Meeting (Abstract CT001) and in The New England Journal of Medicine by Eggermont et al, the phase III EORTC 1325/KEYNOTE 054 trial has shown that adjuvant pembrolizumab (Keytruda) significantly prolonged recurrence-free...
FDA Approves Fostamatinib Disodium Hexahydrate for Chronic Immune Thrombocytopenia in Adult Patients
On April 17, the U.S. Food and Drug Administration (FDA) approved fostamatinib disodium hexahydrate (Tavalisse) for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. Fostamatinib is an oral spleen ...
An Inspiring Experience at Cancer Control for Primary Care Course in Bhutan
I’ll admit it. When I was first asked if I would chair the Cancer Control for Primary Care (CCPC) Course in Bhutan, I immediately exclaimed yes... and then sheepishly went to look up where exactly Bhutan was on a map. For the uninitiated, Bhutan is a country nestled between India and Tibet in the...
2018 Quality Payment Program: ASCO’s Top 10 Things to Know
The second year of the Quality Payment Program (QPP), established by the Medicare Access and CHIP Reauthorization Act (MACRA), began on January 1, 2018. This year, oncology practices face more robust quality reporting requirements to successfully participate in QPP and avoid a financial penalty in...
ASCO Launches New Website Focused on the Business of Oncology
ASCO is launching ASCO Practice Central, a new website that serves as an online information hub to help oncology professionals navigate a complicated and ever-changing practice environment while providing high-quality patient care. The first ASCO website dedicated to the business of oncology, ASCO...
Educate Patients on Safe Storage and Disposal of Pain Medications With ASCO Answers
National Prescription Drug Take Back Day is April 28, 2018. Help ASCO educate patients about how to dispose of unused or expired medications by equipping them with the ASCO Answers fact sheet on Safe Storage and Disposal of Pain Medications. Download a free copy at www.cancer.net/ascoanswers or...
ASCO Honors Leaders in Cancer Care With 2018 Special Awards
ASCO and ASCO’s Conquer Cancer Foundation are proud to recognize the winners of ASCO’s Special Awards and Conquer Cancer’s Women Who Conquer Cancer Mentorship Awards. The recipients of these awards include researchers, patient advocates, and global oncology leaders who have worked to transform...
NCCN Honors Contributors to the Improvement of Global Cancer Care
THE NATIONAL COMPREHENSIVE Cancer Network® (NCCN®) announced the recipients of the 2018 awards for service to patients and contributions to the alliance, during the NCCN 23rd Annual Conference in Orlando, Florida. The awards were presented by NCCN Chief Executive Officer Robert W. Carlson, MD, and...
Skin Cancer Foundation Awards Research Grants
DURING THE RECENT American Academy of Dermatology Annual Meeting in San Diego, The Skin Cancer Foundation hosted a reception to announce the winners of its annual research grant awards. The Skin Cancer Foundation’s grants program provides research funding to support dermatology department research...
Updated NCCN Guidelines® for Newly Diagnosed Glioblastoma
THE NATIONAL COMPREHENSIVE Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology for Central Nervous System Cancers (NCCN Guidelines®) to recommend alternating electric field therapy (also known as tumor-treating fields, Optune) in combination with temozolomide as a...
AACR Announces 2018 Class of Fellows
THE AMERICAN ASSOCIATION for Cancer Research (AACR) recently announced its newly elected class of Fellows of the AACR Academy. The mission of the AACR Academy is to recognize and honor distinguished scientists whose major scientific contributions have propelled significant innovation and progress...
A Clinician’s Guide to Treating Patients With Glioblastoma
Glioblastoma, a grade 4 astrocytoma, is the most common and most aggressive form of primary brain tumors in adults. The most recent guidance on molecular profiling, diagnostic and prognostic factors, and treatments for newly diagnosed and recurrent diseases was described in the Journal of Oncology ...
A Career Based on Service: Both Medical and Military
For this installment in the Living a Full Life series of articles, Edith Peterson Mitchell, MD, was interviewed by Guest Editor Jame Abraham, MD, FACP. Dr. Mitchell is Clinical Professor of Medicine and Medical Oncology in the Division of Medical Oncology at Thomas Jefferson University as well as ...
NIH Completes In-Depth Genomic Analysis
RESEARCHERS FUNDED by the National Institutes of Health (NIH) have completed a detailed genomic analysis, known as the Pan-Cancer Atlas, on a data set of molecular and clinical information from over 10,000 tumors representing 33 types of cancer. The Pan-Cancer Atlas, published as a collection of...
Fine-Tuning Treatment in Myeloma and Leukemia
It is a difficult task to include every notable presentation from the 2017 American Society of Hematology (ASH) Annual Meeting & Exposition. In addition to our more comprehensive coverage of the news from that meeting over the past several issues, below are summaries of additional key...
Expert Point of View: Marisa Weiss, MD
At a press conference where the findings by Chlebowski et al were presented, Marisa Weiss, MD, Founder and Chief Medical Officer of Breastcancer.org and Director of Radiation Oncology at Lankenau Medical Center in Philadelphia, commended this study. “We could set a goal of losing 5 pounds for our...
Modest Weight Loss Reduces Breast Cancer Risk
Evidence of the numerous health benefits of weight loss continues to mount, and the hope is that doctors and patients are listening. A large observational study presented at the 2017 San Antonio Breast Cancer Symposium showed that weight loss of more than 5% is associated with a significantly lower ...
AACR 2018: KEYNOTE-189: Addition of Pembrolizumab to Chemotherapy in Metastatic NSCLC
As reported at the American Association for Cancer Research (AACR) Meeting (Abstract CT075) in the The New England Journal of Medicine by Gandhi et al, the first interim analysis of the phase III KEYNOTE-189 trial has shown significant improvement in overall and progression-free survival with the...
Expert Point of View: C. Kent Osborne, MD
C. Kent Osborne, MD, Director of the Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, and moderator of a press conference where the EMBRACA findings were presented, shared his thoughts on the study. While a few months’ improvement in the risk of disease progression may seem...
AACR 2018: CheckMate 227: Nivolumab/Ipilimumab vs Chemotherapy in NSCLC With High Tumor Mutational Burden Analysis
As reported at the 2018 American Association for Cancer Research (AACR) Meeting (Abstract CT077) and in The New England Journal of Medicine by Hellmann et al, an analysis from the phase III CheckMate 227 trial has shown that the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy)...
Talazoparib Reduces Risk of Disease Progression in BRCA-Mutated Breast Cancer
In patients with BRCA-positive advanced breast cancer, talazoparib reduced the risk of disease progression or death by 46% vs chemotherapy, according to the phase III EMBRACA trial presented at the 2017 San Antonio Breast Cancer Symposium.1 “We are very pleased that the EMBRACA trial—the largest...
Distress Screening: ‘Underestimated and Overlooked’ by Cancer Specialists
The National Comprehensive Cancer Network® (NCCN®) Distress Thermometer and Problem List for Patients have been around since 1999,1 and in 2015, the American College of Surgeons Commission on Cancer mandated routine distress screening at cancer centers.2 So how successful has the cancer community...
Scott Weir, PharmD, PhD, Recipient of 2018 Janet Davison Rowley Patient Impact Research Award
Cures Within Reach, a leading global nonprofit organization focused on drug repurposing research, announced that Scott Weir, PharmD, PhD, of The University of Kansas Cancer Center, is the recipient of the 2018 Janet Davison Rowley Patient Impact Research Award. Dr. Weir serves as Director of the...
Elaine R. Mardis, PhD, Named AACR President-Elect for 2018–2019
The members of the American Association for Cancer Research (AACR) have elected Elaine R. Mardis, PhD, as President-Elect for 2018–2019. She officially became President-Elect at the 2018 AACR Annual Meeting, held in Chicago, April 14–18, and will assume the presidency in April 2019 at the 2019...
Leslie Bernstein, PhD, Receives AACR–American Cancer Society Award for Research Excellence
Biostatistician and epidemiologist Leslie Bernstein, PhD, Professor in the Division of Biomarkers of Early Detection and Prevention, Department of Population Sciences, at City of Hope, has been selected to receive the American Association for Cancer Research’s (AACR) 27th Annual American Cancer...
American Psychosocial Oncology Society Welcomes New President, President-Elect
Teresa Deschields, PhD, is the 2018 President of the American Psychosocial Oncology Society (APOS). Dr. Deschields assumed the role of President during the Society’s annual meeting held recently in Tucson. Dr. Deschields is Clinical Associate Professor in the Department of Medicine at the...
Meeting the Challenges of Providing Long-Term Psychosocial Care for Cancer Survivors
Focusing on the first year after a cancer diagnosis is necessary, but not sufficient, for delivering care to cancer survivors, according to Deborah Mayer, PhD, RN, Director of Cancer Survivorship at the UNC Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill....
Health-Related Quality-of-Life Analysis of Anti–PD-1 Therapy vs Chemotherapy in Advanced Urothelial Cancer
As reported by Vaughn et al in the Journal of Clinical Oncology, a health-related quality-of-life analysis from the phase III KEYNOTE-045 trial in previously treated advanced urothelial cancer showed that patients treated with the anti–programmed cell death protein 1 immunotherapy...
